《风险提示》首个披露的案例，聚焦近期高发的"农业云养殖"领域。据介绍，某地市民孙女士经朋友介 绍，接触到一款"云养黑猪"投资项目。该平台对外宣称，投资者无需实地参与养殖，认购后即可享受年 化60%的固定收益。孙女士投入资金后，平台以"系统升级"为由冻结提现功能，随后关闭APP。经查， 该项目无真实养殖场，利用层级返利发展4万会员，涉案金额超亿元，涉嫌非法传销活动。 深圳市委金融办特别提示，近年来，"云养经济"领域违法犯罪活动高发。一些不法分子往往打着"发展 农业产业"的幌子，将正常的农产品种养、销售环节包装成"投资融资项目"，借助互联网平台广泛宣传 推广，从事违法犯罪活动，既侵害公众合法利益，也对农业产业健康发展造成负面影响。 据了解，此类欺诈活动存在三大典型特征：一是以"农业+科技"为噱头，炒作田园生活、有机生态、智 慧农业等热点，伪造养殖、种植的视频图片来虚构或夸大实际生产场景，对外宣称低风险、高收益，但 真实经营模式难以支撑其承诺收益；二是网络属性强，不法分子依托互联网、移动应用程序开展运营， 通过网上支付工具收付资金，风险波及范围广、扩散速度快，资金监管和追踪难度大；三是存在多种违 法犯罪风险，不法分 ...

10月9日，爱尔眼科盘中上涨2.03%，截至10:48，报12.59元/股，成交6.35亿元，换手率0.65%，总市值 1174.07亿元。 截至6月30日，爱尔眼科股东户数34.39万，较上期减少1.00%；人均流通股23064股，较上期增加 1.01%。2025年1月-6月，爱尔眼科实现营业收入115.07亿元，同比增长9.12%；归母净利润20.51亿元， 同比增长0.05%。 资金流向方面，主力资金净流入5899.52万元，特大单买入1.38亿元，占比21.72%，卖出5138.55万元， 占比8.10%；大单买入1.10亿元，占比17.33%，卖出1.37亿元，占比21.65%。 爱尔眼科今年以来股价跌3.83%，近5个交易日涨0.88%，近20日跌0.55%，近60日涨2.27%。 资料显示，爱尔眼科医院集团股份有限公司位于湖南省长沙市天心区芙蓉南路一段188号爱尔大厦，成 立日期2003年1月24日，上市日期2009年10月30日，公司主营业务涉及向患者提供各种眼科疾病的诊 断、治疗及医学验光配镜等眼科医疗服务。主营业务收入构成为：屈光项目40.13%，视光服务项目 23.64%，白内障项目15 ...

Core Viewpoint - Chao Hong Ji's stock price has seen significant fluctuations, with a year-to-date increase of 160.07%, but recent declines in the short term [1][2] Group 1: Stock Performance - On September 30, Chao Hong Ji's stock rose by 2.05%, reaching 14.46 CNY per share, with a trading volume of 1.32 billion CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 12.848 billion CNY [1] - The stock has experienced a decline of 6.29% over the last five trading days, 12.36% over the last 20 days, and 5.24% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on June 5, where it recorded a net purchase of 1.30 billion CNY [1] Group 2: Company Overview - Chao Hong Ji, established on March 7, 1996, and listed on January 28, 2010, is based in Shantou, Guangdong, and specializes in high-end fashion jewelry design, research, production, and sales, along with handbag business [2] - The revenue composition includes fashion jewelry products (48.53%), traditional gold products (44.63%), brand agency and franchise services (3.00%), leather goods (2.99%), and other products (0.86%) [2] - As of June 30, 2025, the company reported a revenue of 4.102 billion CNY, a year-on-year increase of 19.54%, and a net profit attributable to shareholders of 331 million CNY, up 44.34% [2] Group 3: Shareholder Information - Chao Hong Ji has distributed a total of 1.897 billion CNY in dividends since its A-share listing, with 800 million CNY distributed in the last three years [3] - As of June 30, 2025, the number of shareholders increased by 51.55% to 40,400, with an average of 21,446 circulating shares per shareholder, a decrease of 33.99% [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.1406 million shares, and several new entrants among the top ten circulating shareholders [3]

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 192.23%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

9月30日，锐科激光盘中上涨2.06%，截至11:05，报26.32元/股，成交1.56亿元，换手率1.15%，总市值 148.66亿元。 截至9月19日，锐科激光股东户数4.24万，较上期增加5.24%；人均流通股12299股，较上期减少4.98%。 2025年1月-6月，锐科激光实现营业收入16.64亿元，同比增长4.85%；归母净利润7309.07万元，同比减 少23.78%。 分红方面，锐科激光A股上市后累计派现2.72亿元。近三年，累计派现1.53亿元。 资金流向方面，主力资金净流入809.35万元，特大单买入627.67万元，占比4.02%，卖出603.37万元，占 比3.86%；大单买入3687.83万元，占比23.60%，卖出2902.78万元，占比18.57%。 锐科激光今年以来股价涨37.73%，近5个交易日跌0.08%，近20日跌16.07%，近60日涨7.42%。 资料显示，武汉锐科光纤激光技术股份有限公司位于湖北省武汉市东湖新技术开发区未来科技城龙山南 街一号，成立日期2007年4月6日，上市日期2018年6月25日，公司主营业务涉及从事光纤激光器及其关 键器件与材料的研发、生产和销 ...

Core Viewpoint - Innovation Medical's stock has shown significant volatility, with a year-to-date increase of 157.54%, but recent declines in the short term indicate potential market fluctuations [1][2]. Group 1: Stock Performance - On September 29, Innovation Medical's stock rose by 2.09%, reaching 20.50 CNY per share, with a trading volume of 4.36 billion CNY and a turnover rate of 5.17%, resulting in a total market capitalization of 90.46 billion CNY [1]. - Year-to-date, the stock has increased by 157.54%, but it has decreased by 4.78% over the last five trading days and 18.62% over the last 20 days, while showing a 35.14% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" 18 times this year, with the most recent appearance on September 5, where it recorded a net buy of -1.21 billion CNY [1]. Group 2: Financial Performance - For the first half of 2025, Innovation Medical reported a revenue of 402 million CNY, reflecting a year-on-year decrease of 1.60%, while the net profit attributable to the parent company was -11.36 million CNY, showing a year-on-year increase of 29.12% [2]. - Since its A-share listing, the company has distributed a total of 55.87 million CNY in dividends, with no dividends paid in the last three years [2]. Group 3: Shareholder Information - As of June 30, the number of shareholders for Innovation Medical was 82,000, an increase of 20.38% from the previous period, with an average of 5,074 circulating shares per person, a decrease of 16.93% [2].

分红方面，锐科激光A股上市后累计派现2.72亿元。近三年，累计派现1.53亿元。 机构持仓方面，截止2025年6月30日，锐科激光十大流通股东中，南方中证1000ETF（512100）位居第 七大流通股东，持股313.02万股，相比上期增加60.30万股。香港中央结算有限公司位居第八大流通股 东，持股243.05万股，相比上期减少57.31万股。华夏中证1000ETF（159845）位居第十大流通股东，持 股184.31万股，为新进股东。 资料显示，武汉锐科光纤激光技术股份有限公司位于湖北省武汉市东湖新技术开发区未来科技城龙山南 街一号，成立日期2007年4月6日，上市日期2018年6月25日，公司主营业务涉及从事光纤激光器及其关 键器件与材料的研发、生产和销售。主营业务收入构成为：连续光纤激光器81.88%，脉冲光纤激光器 9.29%，其他4.46%，超快激光器2.47%，特种光纤1.90%。 锐科激光所属申万行业为：机械设备-自动化设备-激光设备。所属概念板块包括：商业航天（航天航 空）、医疗美容、航天军工、中盘、湖北自贸区等。 截至9月19日，锐科激光股东户数4.24万，较上期增加5.24%；人均流通股 ...

Core Viewpoint - Aimeike's stock price has shown fluctuations with a recent increase of 2.01%, while the company faces a decline in revenue and profit for the first half of 2025 compared to the previous year [1][2]. Financial Performance - As of September 19, 2025, Aimeike reported a revenue of 1.299 billion yuan, a year-on-year decrease of 21.59%, and a net profit attributable to shareholders of 789 million yuan, down 29.57% year-on-year [2]. - The company has distributed a total of 3.887 billion yuan in dividends since its A-share listing, with 3.012 billion yuan distributed over the past three years [3]. Stock Market Activity - On September 26, Aimeike's stock was priced at 183.47 yuan per share, with a market capitalization of 55.517 billion yuan and a trading volume of 393 million yuan [1]. - The stock has increased by 3.35% year-to-date, but has seen a decline of 1.12% over the last five trading days and 4.83% over the last twenty days [1]. Shareholder Information - As of September 19, 2025, Aimeike had 56,400 shareholders, an increase of 3.28% from the previous period, with an average of 3,700 circulating shares per shareholder, a decrease of 3.17% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and various ETFs, with some shareholders increasing or decreasing their holdings [3].

Core Viewpoint - Fangsheng Pharmaceutical has shown a positive stock performance with a year-to-date increase of 20.68% and a recent surge of 12.06% over the past five trading days, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2]. - The top ten circulating shareholders include notable institutional investors, with ICBC Medical Health Stock holding 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed Fund increasing its holdings by 500,000 shares to 5 million [3]. Market Activity - On September 26, Fangsheng Pharmaceutical's stock price rose by 2.11% to 12.08 yuan per share, with a trading volume of 125 million yuan and a turnover rate of 2.42%, resulting in a total market capitalization of 5.304 billion yuan [1]. - The net inflow of main funds was 4.67 million yuan, with significant buying activity from large orders, indicating strong investor interest [1].